BC
Boxer Capital Portfolio holdings
AUM
$2.04B
This Quarter Return
+42.04%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$2.01B
AUM Growth
+$2.01B
(+6.8%)
Cap. Flow
-$242M
Cap. Flow
% of AUM
-12.04%
Top 10 Holdings %
Top 10 Hldgs %
57.08%
Holding
77
New
4
Increased
7
Reduced
4
Closed
25
Top Buys
| 1 |
argenx
ARGX
|
$28.5M |
| 2 |
Arvinas
ARVN
|
$25.1M |
| 3 |
Structure Therapeutics
GPCR
|
$16.3M |
| 4 |
Tango Therapeutics
TNGX
|
$10.6M |
| 5 |
Immunovant
IMVT
|
$10.5M |
Top Sells
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$38.2M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$36.5M |
| 3 |
Ventyx Biosciences
VTYX
|
$29.5M |
| 4 |
Amicus Therapeutics
FOLD
|
$28.3M |
| 5 |
Exelixis
EXEL
|
$25.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $188M | 9.37% | 3,201,440 | – | – |
|
2
Cytokinetics
CYTK
$4.23B
| $175M | 8.74% | 2,100,000 | – | – |
|
|
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
| $125M | 6.22% | 3,421,541 | – | – |
|
4
Revolution Medicines
RVMD
$7.1B
| $123M | 6.12% | 4,279,464 -404,800 | -9% | -$11.6M |
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $103M | 5.15% | 1,726,000 | – | – |
|
|
ONC
6
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $90.2M | 4.49% | 500,000 | – | – |
|
7
Tyra Biosciences
TYRA
$675M
| $89.3M | 4.45% | 6,448,359 | – | – |
|
|
IMGN
8
DELISTED
Immunogen Inc
IMGN
| $87.8M | 4.38% | 2,961,000 | – | – |
|
9
Nuvalent
NUVL
$5.52B
| $82.4M | 4.11% | 1,120,192 -90,000 | -7% | -$6.62M |
|
|
10
Tango Therapeutics
TNGX
$747M
| $81.2M | 4.05% | 8,198,642 +1,075,000 | +15% | +$10.6M |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $79.1M | 3.94% | 250,000 | – | – |
|
12
IDEAYA Biosciences
IDYA
$2.15B
| $78.4M | 3.91% | 2,202,812 | – | – |
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $62.7M | 3.12% | 650,000 +50,000 | +8% | +$4.82M |
|
|
14
argenx
ARGX
$43.6B
| $60.9M | 3.03% | 160,000 +75,000 | +88% | +$28.5M |
|
15
Merus
MRUS
$4.98B
| $52.3M | 2.6% | 1,900,000 | – | – |
|
16
Rocket Pharmaceuticals
RCKT
$354M
| $43.9M | 2.19% | 1,466,051 | – | – |
|
|
17
Immunovant
IMVT
$2.56B
| $42.1M | 2.1% | 1,000,000 +250,000 | +33% | +$10.5M |
|
18
Akero Therapeutics
AKRO
$3.74B
| $39.2M | 1.95% | 1,676,733 | – | – |
|
19
Legend Biotech
LEGN
$6.41B
| $36.1M | 1.8% | 600,000 | – | – |
|
20
Axsome Therapeutics
AXSM
$6.05B
| $31.8M | 1.59% | 400,000 | – | – |
|
21
Arcus Biosciences
RCUS
$1.13B
| $30.6M | 1.53% | 1,602,200 | – | – |
|
22
AnaptysBio
ANAB
$569M
| $27.8M | 1.39% | 1,300,000 | – | – |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $27.6M | 1.38% | 600,000 | – | – |
|
|
24
Arvinas
ARVN
$568M
| $25.1M | 1.25% | +608,614 | New | +$25.1M |
|
25
Prothena Corp
PRTA
$441M
| $24.2M | 1.2% | 665,000 +40,000 | +6% | +$1.45M |
|